Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 1)

NCT07023627 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT07023627
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07023627 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 1)
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Recruiting
Start date
November 12, 2025
Completion date
October 24, 2027
Enrollment
160 (estimated)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer